20260109 CRISPR Therapeutics - JPM 2026.pdf

1、CRISPR Corporate Update44thAnnual J.P.Morgan Healthcare ConferenceJanuary 12,20261 2026 CRISPR TherapeuticsForward-Looking Statements2This presentation and related materials may contain statements regarding matters that are not historical facts and are“forward-looking statements”within the meaning o

2、f the Private Securities Litigation Reform Act of 1995.Because such statements are subject to risks and uncertainties,actual results may differ materially from those expressed or implied by such forward-looking statements.Such statements include,but are not limited to,statements regarding any or all

3、 of the following:(i)CRISPR Therapeutics preclinical studies,clinical trials and pipeline products and programs,including,without limitation,manufacturing capabilities,status of such studies and trials,potential expansion into new indications and expectations regarding data,safety and efficacy gener

4、ally;(ii)data included in this presentation,as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials;(iii)CRISPR Therapeutics strategy,goals,anticipated financial performance and the sufficiency of its cash resources;(iv)reg

5、ulatory submissions and authorizations,including timelines for and expectations regarding regulatory agency decisions;(v)plans and expectations for the commercialization of,and anticipated benefits of,CASGEVY;(vi)the expected benefits of CRISPR Therapeutics collaborations;and(vii)the therapeutic val

6、ue,development,and commercial potential of gene editing technologies and therapies,including CRISPR/Cas9 and SyNTase,as well as other technologies.Risks that contribute to the uncertain nature of the forward-looking statements include,without limitation,the risks and uncertainties discussed under th